Medicare 2024 Diabetes Prescribing Aid
Date:
05/28/24
2024 Diabetes Prescribing Aid MAPD: D-SNP, C-SNP, & PPO
Benefits subject to evidence of coverage. Information on copays/cost sharing, deductibles, and gap coverage can be found in the Summary of Benefits on our website:
H0351, H5590: Wellcare By Allwell H8553: Wellcare
| 2024 Preferred Insulin Products | |
| Fast Acting | - Fiasp (insulin aspart)
- Novolog
|
| Short Acting | - Novolin R (Note: Brand RELION is not covered).
|
| Intermediate Acting | - Novolin N (Note: Brand RELION is not covered)
|
| Long Actiing | - Basaglar (insulin glargine).
- Tresiba (insulin degludec)
- Toujeo (insulin glargine).
- Toujeo Max (insulin glargine)
|
| Combinations | Insulins
- Novolog Mix 70/30.
- Novolin 70/30
Insulin + GLP-1 receptor agonist
- Soliqua (insulin glargine + lixisenatide), Xultophy (insulin degludec+ liraglutide)
|
- C-SNP plans (Wellcare Specialty No Premium HMO C-SNP): Tier 6, $0 or low copay
- D -SNP plans (Wellcare Dual Liberty HMO D-SNP): Tier 1, $0 or low copay.
- All other plans: Tier 3 with maximum copay of $35 per month based on Inflation Reduction Act
| |
For more than 20 years, Wellcare has ofered a range of Medicare products, which ofer afordable coverage beyond OriginalMedicare. Beginning Jan. 1, 2022, our afliated Medicare brands, including Allwell, transitioned to a newly refreshed and unifid Wellcare brand. If you have any questions, please contact Provider Relations.
| 2024 Preferred Anti-Diabetic (non-insulin) Medications |
GENERIC ORAL ANTI-DIABETIC MEDICATIONS:
- Biguanide: metformin, metformin ER (generic for Glucophage XR only).
- Thiazolidinedione: pioglitazone.• Alpha-Glucosidase inhibitor: acarbose.
- Meglitinide analogue: nateglinide, repaglinide.
- Combinations: glipizide/metformin, pioglitazone/metformin, pioglitazone/glimepiride.
|
- C-SNP plans (Wellcare Specialty No Premium HMO C-SNP): Tier 1, $0 or low copay.
- D-SNP plans (Wellcare Dual Liberty HMO D-SNP): Tier 1, $0 or low copay.
- All other plans: Tier 6, $0 or low copay.
|
DPP-4 INHIBITOR:
DPP-4 COMBINATIONS:
- Glyxambi, Janumet, Janumet XR,Jentodueto, Jentodueto XR, Trijardy.
|
- C-SNP plans (Wellcare Specialty No Premium HMO C-SNP): Tier 6, $0 or low copay, EXCEPT Glyxambi and Trijardy, which are Tier 3.
- D-SNP plans (Wellcare Dual Liberty HMO D-SNP): Tier 1, $0 or low copay.
- All other plans: Tier 3.
|
SGLT-2 INHIBITOR:
- Farxiga, Jardiance, Invokana.
SGLT-2 INHIBITOR COMBINATION:
- Glyxambi, Synjardy, Synjardy XR, Trijardy,Xigduo, Invokamet*, Invokamet XR.*
|
- *Invokana, Invokamet, and Invokamet XR: NONFORMULARY for D-SNP plans (Wellcare DualLiberty HMO D-SNP) and Tier 4 for all other plans.
- Farxiga, Jardiance – Tier 1, $0 or low copay, for D-SNP plans (Wellcare Dual Liberty HMO D-SNP),and Tier 3 for all other plans.
|
GLP-1 AGONIST:
- Bydureon, Ozempic, Mounjaro, Rybelsus, Trulicity.
|
- D -SNP plans (Wellcare Dual Liberty HMO D-SNP): Tier 1, $0 or low copay.
- All other plans: Tier 3.
- All plans require prior authorization.
|
2024 Preferred Blood Glucose Meters and Strips
One Touch Verio Reflect or Verio Flex meter and One Touch Verio test strips; One Touch Ultra 2meter and One Touch Ultra test strips
|
Test Strip Quantity Limits:
- Non-insulin users: 100 strips/90 days
- Insulin users: 100 strips/25 days
|
| Note: Continuous Glucose Monitoring (CGM) systems require Prior Authorization(PA). FreeStyle Libre or DexCom are preferred/PA required. PA criteria: DM diagnosis, insulin-treated, has had more than one level 2 hypoglycemic event (BG < 54 mg/dL) that persists despite more than one attempt toadjust medications and/or modify diabetes treatment plan OR one level 3 hypoglycemic event (BG< 54 mg/dL) characterized by altered mental and/or physical state requiring third-party assistancefor treatment, seen by provider in last six months, and will have follow-up appointments every sixmonths to document adherence to both the CGM regimen and diabetes treatment plan. The CoverageDetermination form for PA request is available on our website. |